je.st
news
Tag: bristolmyers
Bristol-Myers Squibb Works hard to be a Good Neighbor
2013-08-12 22:15:00| Chemical Processing
Bristol-Myers Squibb manually monitored dissolved oxygen (DO) periodically and ran aeration blowers more than necessary to guard against variable loading rates. After upgrading the system to use online DO monitoring operators now have continuous DO readings in the aeration tanks, substantially reducing energy and maintenance costs.
Tags: good
works
hard
neighbor
Bristol-Myers To Cut 200 NJ Jobs
2013-07-23 23:28:59| Biotech - Topix.net
Bristol-Myers Squibb Co. says it plans to eliminate the jobs of about 200 support service workers at its Plainsboro and other central New Jersey offices.
Tags: jobs
cut
cut 200
bristolmyers
Former Bristol-Myers executive admits to insider trading
2013-06-11 04:05:06| Biotech - Topix.net
A former Bristol-Myers Squibb Co finance executive on Monday pleaded guilty to an insider trading charge, admitting to buying stock options in a biotechnology company that the drugmaker was preparing to buy.
Tags: executive
trading
insider
admits
Bristol-Myers Squibb drug study showed effectiveness against advanced melanoma cancer
2013-05-18 18:06:01| Biotech - Topix.net
Two drugs from Bristol-Myers Squibb Co. shrank tumors in as many as half of patients with advanced melanoma, according to early research that may pave the way for cocktails that trigger the immune system to destroy cancer.
Tags: advanced
study
drug
showed
Merck Enters Agreement with Bristol-Myers Squibb to Conduct a Phase II Clinical Trial Evaluating Combination of Investigational Oral Candidates MK-5172 and Daclatasvir for Chronic Hepatitis C
2013-04-22 13:30:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK) today announced it has entered into a non-exclusive agreement with Bristol-Myers Squibb to conduct a Phase II clinical trial to evaluate the safety and efficacy of a once-daily oral combination regimen consisting of Bristol-Myers Squibbs investigational NS5A replication complex inhibitor daclatasvir and Merck's investigational NS3/4A protease inhibitor MK-5172 for the treatment of chronic hepatitis C virus (HCV) infection, genotype 1. Language: English Contact HTML: MerckMedia:Caroline Lappetito, (267) 305-7639orInvestor:Carol Ferguson, (908) 423-4465Justin Holko, (908) 423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: c
agreement
trial
combination
Sites : [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] next »